---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-158944"
form_type: "8-K"
ticker: "AKTS"
cik: "0002035832"
company_name: "Aktis Oncology, Inc."
filed_at: "2026-04-16T23:59:59+00:00"
generated_at: "2026-05-15T05:56:09.605392+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "high"
source: SEC EDGAR
---

# Aktis Oncology appoints Glenn Gormley to board; two directors resign

## Summary
- Glenn Gormley, MD, PhD appointed independent director and co-chair of new Science and Technology Committee, effective April 15, 2026.
- Gormley, 72, previously Global Head of R&D at Daiichi Sankyo; over 30 years biopharma leadership.
- Received option for 37,866 shares vesting over three years; annual cash compensation $45,000 plus $15,000 for committee role.
- Helen S. Kim and Oleg Nodelman resign from board effective May 20, 2026; not due to any disagreement.
- Gormley joins as company advances clinical milestones in targeted radiopharmaceuticals.

## SEC filing metadata
- accession: 0001193125-26-158944
- form_type: 8-K
- ticker: AKTS
- cik: 0002035832
- company_name: Aktis Oncology, Inc.
- filed_at: 2026-04-16T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/2035832/000119312526158944/0001193125-26-158944-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/2035832/000119312526158944/d110479d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-158944
- JSON: https://secwatch.observer/filing/0001193125-26-158944.json
- Plain text: https://secwatch.observer/filing/0001193125-26-158944.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.